AUSTEDO (Teva Pharma Australia Pty Ltd)
Product name
AUSTEDO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
190 (255 working days)
Active ingredients
deutetrabenazine
Registration type
NCE/NBE
Indication
AUSTEDO (modified release tablet) is indicated for the treatment of:
- chorea associated with Huntington's disease
- tardive dyskinesia in adults